Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Calandra

Showing results (71-80 of 99) with videos related to

Pageof 10
Sort By:
Infection and Immunity|March 18, 2000
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemiaJ A Martiney, B Sherry, C N Metz, et al.
Swiss Medical Weekly|February 24, 2001
CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumoniaI de Werra, G Zanetti, C Jaccard, et al.
The Journal of Infectious Diseases|May 1, 1990
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study GroupT Calandra, J D Baumgartner, G E Grau, et al.
Nature|October 21, 1993
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemiaJ Bernhagen, T Calandra, R A Mitchell, et al.
British Journal of Haematology|June 10, 2000
Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5)R Walter, G Schoedon, E Bächli, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1995
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of CancerA Cometta, S Zinner, R de Bock, et al.
Nature Medicine|February 2, 2000
Protection from septic shock by neutralization of macrophage migration inhibitory factorT Calandra, B Echtenacher, D L Roy, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1988
Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trialsJ Klastersky, S H Zinner, T Calandra, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 6, 2013
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of SwitzerlandC Orasch, O Marchetti, J Garbino, et al.
The American Journal of Pathology|January 1, 1997
Migration inhibitory factor expression in experimentally induced endotoxemiaM Bacher, A Meinhardt, H Y Lan, et al.
Pageof 10

Showing results (71-80 of 99) with videos related to

Sort By:
Pageof 10
Infection and Immunity|March 18, 2000
Macrophage migration inhibitory factor release by macrophages after ingestion of Plasmodium chabaudi-infected erythrocytes: possible role in the pathogenesis of malarial anemiaJ A Martiney, B Sherry, C N Metz, et al.
Swiss Medical Weekly|February 24, 2001
CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumoniaI de Werra, G Zanetti, C Jaccard, et al.
The Journal of Infectious Diseases|May 1, 1990
Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study GroupT Calandra, J D Baumgartner, G E Grau, et al.
Nature|October 21, 1993
MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemiaJ Bernhagen, T Calandra, R A Mitchell, et al.
British Journal of Haematology|June 10, 2000
Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5)R Walter, G Schoedon, E Bächli, et al.
Antimicrobial Agents and Chemotherapy|February 1, 1995
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of CancerA Cometta, S Zinner, R de Bock, et al.
Nature Medicine|February 2, 2000
Protection from septic shock by neutralization of macrophage migration inhibitory factorT Calandra, B Echtenacher, D L Roy, et al.
European Journal of Cancer & Clinical Oncology|January 1, 1988
Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trialsJ Klastersky, S H Zinner, T Calandra, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 6, 2013
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of SwitzerlandC Orasch, O Marchetti, J Garbino, et al.
The American Journal of Pathology|January 1, 1997
Migration inhibitory factor expression in experimentally induced endotoxemiaM Bacher, A Meinhardt, H Y Lan, et al.
Pageof 10